Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents

Introduction The incidence rate and risk factors of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) in prostate cancer patients with bone metastasis are not clear. Materials and Methods We retrospectively reviewed patients’ records of prostate cancer patients with bone metastasis who w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bone and mineral metabolism 2021-03, Vol.39 (2), p.295-301
Hauptverfasser:	Nakai, Yasutomo, Kanaki, Tomohiro, Yamamoto, Akinaru, Tanaka, Ryo, Yamamoto, Yoshiyuki, Nagahara, Akira, Nakayama, Masashi, Kakimoto, Ken-ichi, Ishibashi, Miki, Nishimura, Kazuo
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Bisphosphonate-Associated Osteonecrosis of the Jaw - complications Bone and Bones - pathology Bone cancer Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - therapeutic use Bone Neoplasms - drug therapy Bone Neoplasms - secondary Calcium Calcium (blood) Castration Chemotherapy Disease-Free Survival Humans Immunotherapy Jaw Male Medicine Medicine & Public Health Metabolic Diseases Metastases Metastasis Middle Aged Monoclonal antibodies Multivariate analysis Original Article Orthopedics Osteonecrosis Prostate cancer Prostatic Neoplasms - complications Prostatic Neoplasms - drug therapy Retrospective Studies Risk Factors Survival Targeted cancer therapy Zoledronic acid Zoledronic Acid - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!